Farrell Simon
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Farrell Simon
The proxy statement of Trevi Therapeutics, Inc. reports total compensation of $1,355,897 for Farrell Simon in fiscal 2025, including a base salary of $370,067. Disclosed compensation is on record for 2 fiscal years. Farrell Simon has spoken on 2 earnings calls across 1 company, most recently for Trevi Therapeutics, Inc. on August 6, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Trevi Therapeutics, Inc. (TRVI)
Source not stated
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Trevi Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Christopher Galletta Chief Accounting Officer
- Anne VanLent Board Member
- Dominick C. Colangelo Board Member
- James V. Cassella Board Member
- Jennifer Good Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Trevi Therapeutics, Inc. (TRVI) | Pharm. D. Chief Commercial Officer | $370,067 | $1,355,897 |
| 2024 | Trevi Therapeutics, Inc. (TRVI) | Pharm. D. Chief Commercial Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.